The globus pallidus (GP) is a central node in the basal ganglia motor circuit and exhibits significant involvement in corticobasal degeneration (CBD), a pathologically distinct 4R tauopathy. [1][2] As part of the indirect pathway that modulates motor execution, pallidal dysfunction contributes to the characteristic rigidity, bradykinesia, and dystonia observed in corticobasal syndrome (CBS). CBD-related tau pathology affects both the external segment (GPe) and internal segment (GPi), leading to disrupted inhibitory output and network-level hyperexcitability. [3][4]
Understanding GP involvement in CBD is critical because the pallidum serves as a convergence point for cortical input modulation, striatal processing, and thalamic feedback. Its strategic position means that pallidal pathology amplifies motor impairments beyond what primary cortical or striatal lesions would predict.
The globus pallidus consists of two histologically and functionally distinct segments:
Globus pallidus external segment (GPe): The primary inhibitory output of the indirect pathway, receiving input from striatum and projecting to the subthalamic nucleus (STN). GPe neurons provide tonic inhibition that normally prevents excessive STN excitation. [5][6]
Globus pallidus internal segment (GPi): The main output nucleus of the basal ganglia, delivering inhibitory signals to the thalamus and brainstem motor centers. GPi activity determines the overall excitatory state of thalamocortical circuits. [5:1][7]
GP neurons are large, densely packed GABAergic projection neurons with extensive dendritic arborization. They exhibit high firing rates under baseline conditions and receive convergent input from multiple basal ganglia nodes. The high metabolic demand and extensive axonal projections make pallidal neurons vulnerable to proteostasis disruption. [8]
The GP integrates information across multiple parallel loops:
In CBD, tau pathology disrupts all three loops, though motor symptoms dominate early presentation.
CBD is classified as a primary 4R tauopathy with characteristic lesions including astrocytic plaques, coiled bodies, thread pathology, and neuronal inclusions. [1:1][2:1] In the globus pallidus, these manifest as:
Several interconnected mechanisms drive pallidal vulnerability in CBD:
CBD typically presents with asymmetric cortical and subcortical involvement. Pallidal pathology often aligns with contralateral cortical atrophy, producing the characteristic unilateral apraxia that precedes bilateral progression. This lateralization can be useful for differentiating CBS from more symmetric atypical parkinsonisms. [10][11]
Pallidal dysfunction contributes to several core CBS manifestations:
Pallidal involvement affects axial motor control:
Levodopa responsiveness in CBS is typically poor compared with idiopathic PD: [4:2][@burrell2020]
Structural MRI in CBD may show:
Functional imaging can reveal:
Plasma and CSF markers under investigation include: [12]
Pallidal involvement helps differentiate CBS from:
Given mixed cortical-subcortical pathophysiology, management emphasizes:
The GP represents a meaningful therapeutic target because: [14]
Emerging anti-tau therapies may provide particular benefit for pallidal involvement, as tau pathology is the primary driver of neuronal dysfunction.
Research priorities include:
Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002. ↩︎ ↩︎
Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011. ↩︎ ↩︎
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. ↩︎
Stamelou M, Quinn NP, Bhatia KP. Atypical parkinsonism: advances in diagnosis and management. J Neurol Neurosurg Psychiatry. 2017. ↩︎ ↩︎ ↩︎
DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007. ↩︎ ↩︎
Graybiel AM. The basal ganglia. Curr Biol. 2000. ↩︎
Nambu A. Globral organization of the primate basal ganglia: three systems for motor execution. Neurosci Res. 2020. ↩︎
Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014. ↩︎ ↩︎
Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2019. ↩︎
Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010. ↩︎
Burrell JR, Hodges JR, Rowe JB. Corticobasal syndrome: a practical guide. Pract Neurol. 2014. ↩︎ ↩︎
Leuzy A, Ashton NJ, Mattsson-Carlgren N, et al. Tau PET and fluid biomarkers in primary tauopathies. Nat Rev Neurol. 2024. ↩︎
Schootemeijer S, van der Kolk NM, Bloem BR, et al. Physiotherapy and multidisciplinary care for progressive supranuclear palsy and corticobasal syndrome. Parkinsonism Relat Disord. 2023. ↩︎
Dam T, Boxer AL, Golbe LI, et al. Emerging disease-modifying therapies for PSP and CBD. J Neurol Neurosurg Psychiatry. 2022. ↩︎